Portal de investigación
Towards precision oncology for anti-HER2 blockade in gastroesophageal adenocarcinoma.
Fecha de publicación:
Autores de INCLIVA
Grupos y Plataformas de I+D+i
Abstract
Gastroesophageal adenocarcinoma (GEA) represents a very heterogeneous disease and patients in advanced stages have a very poor prognosis. Although several molecular classifications have been proposed, precision medicine for HER2-amplified GEA patients still represents a challenge. Despite improvement in clinical outcomes obtained by adding trastuzumab to first-line platinum-based chemotherapy, no other anti-HER2 agents used first-line or beyond progression have demonstrated any benefit. Several factors contribute to this failure. Among them, variable HER2 amplification assessment, tumour heterogeneity, molecular mechanisms of resistance and microenvironmental factors could limit the effectiveness of anti-HER2 blockade. Identifying the factors responsible for both primary and acquired resistance is a priority for providing an improved, personalised approach. In this review, we examine current treatments for HER2-amplified GEA, their potential mechanisms of resistance and the ways to overcome them, investigating the most relevant translational studies with anti-HER2 agents in GEA, as well as novel agents under development in this field.
© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com
Datos de la publicación
- ISSN/ISSNe:
- 0923-7534, 1569-8041
- Tipo:
- Review
- Páginas:
- 1254-1264
- PubMed:
- 31046106
ANNALS OF ONCOLOGY OXFORD UNIV PRESS
Citas Recibidas en Web of Science: 22
Documentos
Filiaciones
Keywords
- gastroesophageal cancer; HER2 amplification; tumour heterogeneity; tumour microenvironment; drug resistance; new anti-HER2 drugs
Financiación
Proyectos y Estudios Clínicos
CONTRATOS RIO HORTEGA
Investigador Principal: NOELIA TARAZONA LLAVERO
CM15/00246 . INSTITUTO SALUD CARLOS III
Enfermedad mínima residual en cánceres colorrectales de alto riesgo resecados. Valor de las biopsias líquidas en el seguimiento y análisis de la heterogeneidad tumoral.
Investigador Principal: ANDRÉS CERVANTES RUIPEREZ
PI15/02180 . INSTITUTO SALUD CARLOS III . 2016
CONTRATOS JUAN RODES
Investigador Principal: DESAMPARADOS RODA PEREZ
2016/197 . INSTITUTO SALUD CARLOS III . 2017
JR17/00026 AYUDA JOAN RODÉS DRA. TANIA FLEITAS /2017/322)
Investigador Principal: TANIA CAROLINA FLEITAS KANONNIKOFF
JR17/00026 . INSTITUTO SALUD CARLOS III . 2018
Macrófagos asociados al tumor, angiogénesis tumoral y resistencia a las terapias en Cáncer Gástrico Difuso fenotipo Mesenquimal.
Investigador Principal: TANIA CAROLINA FLEITAS KANONNIKOFF
PI18/01508 . INSTITUTO SALUD CARLOS III . 2019
Medicina personalizada en pacientes con cáncer colorrectal localizado: abordaje multiómico de la Enfermedad Mínima Residual en biopsia líquida y modelos de organoides
Investigador Principal: ANDRÉS CERVANTES RUIPEREZ
PI18/01909 . INSTITUTO SALUD CARLOS III . 2019
Cita
Gambardella V,Fleitas T,Tarazona N,Cejalvo JM,Gimeno F,Martinez C,Huerta M,Rosello S,Castillo J,Roda D,Cervantes A. Towards precision oncology for anti-HER2 blockade in gastroesophageal adenocarcinoma. Ann. Oncol. 2019. 30(8):p. 1254-1264. (1).
Towards precision oncology for anti-HER2 blockade in gastroesophageal adenocarcinoma. Gambardella,V, Fleitas,T, Tarazona,N, Cejalvo,J M, Gimeno Valiente,F, Martinez Ciarpiaglini,C, Huerta,M et al. ANNALS OF ONCOLOGY. 2019 enero 01. 30 (8):1254-1264. DOI:10.1093/annonc/mdz143. PMID:31046106.
